NASDAQ$OABI
OmniAb Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year 2022, with revenue increase primarily due to a milestone payment related to the first commercial sale of TECVAYLI™ in the U.S.
OmniAb reported Q4 2022 revenue of $35.3 million, a significant increase compared to $15.3 million in Q4 2021, driven by a $25.0 million milestone payment from the first commercial sale of TECVAYLI™ in the U.S. Net income for the quarter was $6.8 million, a substantial improvement from the net loss of $3.1 million in the same period last year.
- Revenue for the fourth quarter of 2022 was $35.3 million, compared to $15.3 million for the same period in 2021.
- Net income for the fourth quarter of 2022 was $6.8 million, or $0.07 per diluted share, compared to a net loss of $3.1 million, or $0.04 per share, for the same period in 2021.
- Signed 13 new licenses in 2022, including one in the fourth quarter with the Wistar Institute.
- As of December 31, 2022, the company had 69 active partners with 26 OmniAb-derived programs in clinical development or being commercialized, and a total of 291 programs being pursued or commercialized.
Headline financials
Revenue & EPS history
OmniAb · Revenue · Quarterly
$35.3M
Revenue by segment
OmniAb · $35.3M total across 3 segments · Q4 2022
- License and Milestone$31.1M—88.0%
- Service Revenue$3.86M—10.9%
- Royalty Revenue$383K—1.1%
Forward guidance
The Company expects its 2023 year-end cash, cash equivalents and short-term investments balance to be slightly higher than year-end 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2022
-2.1%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+9.9%
Q4 2025
Best reaction
-20.4%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +29.4% | +72.7% | |
| Q4 2025 | +9.9% | +9.9% | -14.9% | |
| Q3 2025 | -4.1% | +0.7% | +31.8% | |
| Q1 2025 | -7.2% | -3.2% | -4.5% | |
| Q4 2024 | -20.4% | -20.4% | -43.9% | |
| Q3 2024 | -11.5% | -15.7% | -13.0% | |
| Q2 2024 | +4.4% | +4.9% | -2.2% | |
| Q1 2024 | +3.1% | -0.9% | +2.2% | |
| Q4 2023 | -2.5% | +0.8% | -11.4% | |
| Q3 2023 | -6.8% | +3.5% | +7.3% | |
| Q2 2023 | -5.7% | -3.8% | -10.4% | |
| Q1 2023 | +6.1% | +16.1% | +37.3% | |
| Q4 2022 | +9.5% | +10.1% | +3.6% | |
| Q3 2022 | -15.5% | -4.1% | +19.3% | |
| Q2 2022 | +0.2% | +0.1% | +0.3% | |
| Q1 2022 | -0.0% | +0.0% | +0.1% | |
| Q4 2021 | -0.0% | -0.1% | -0.1% | |
| Q3 2021 | +0.0% | +0.0% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro